Completed PHASE1 INTERVENTIONAL NCT00183846

Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers

Phase I Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers

Sponsor: University of Southern California

Conditions Bile Duct Cancer Duodenum Cancer Gastric Cancer Pancreatic Cancer

Interventions irinotecan radiation therapy

Updated 5 times since 2017 Last updated: May 20, 2014 Started: Dec 31, 2000 Primary completion: Oct 31, 2007 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Bile Duct Cancer and Duodenum Cancer and is currently completed. University of Southern California leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Southern California

Data source: University of Southern California

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States